Request Your Free White Paper Now:

"The Emergence of Multi-modal Real-world data"

The power of clinico-genomic data versus traditional RWD sources. Achieving complete and informed drug discovery and clinical development requires the right mix of clinical, claims and other real-world data (RWD).

This resource will explore:

• Why biomarker and genomic data matters
• How these data sources unlock what’s been missing from traditional RWD sources
• How newly created longitudinal data sets support drug development from discovery to trial to post-market
• Why longitudinal data matters for developing targeted treatments for rare or complex conditions such as multiple myeloma
• How tokenization allows for better integration of disparate data sources and meets the scrutiny of peer review and regulatory approval

Offered Free by: NeoGenomics
See All Resources from: NeoGenomics